

Ana Elisa Lohmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7501145/publications.pdf>

Version: 2024-02-01

19
papers

298
citations

1040056

9
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

607
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 4249-4255. | 1.6 | 77 |
| 2 | A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. <i>Breast</i> , 2019, 48, 17-23. | 2.2 | 73 |
| 3 | Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1465-1475. | 6.3 | 50 |
| 4 | Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 605-611. | 2.5 | 19 |
| 5 | Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 451-460. | 2.5 | 15 |
| 6 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050. | 2.9 | 15 |
| 7 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, prz049. | 2.9 | 11 |
| 8 | Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky028. | 2.9 | 10 |
| 9 | Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 371-378. | 2.5 | 9 |
| 10 | Normal Weight Adiposity and Postmenopausal Breast Cancer Risk. <i>JAMA Oncology</i> , 2019, 5, 150. | 7.1 | 7 |
| 11 | The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 529-529. | 1.6 | 3 |
| 12 | Hype versus Hope: Metformin and Vitamin D as Anticancer Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e69-e74. | 3.8 | 2 |
| 13 | Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1161-1162. | 6.3 | 2 |
| 14 | Obesity and Breast Cancer: Expanding the Hypothesis Space. <i>Journal of the National Cancer Institute</i> , 2021, 113, 107-108. | 6.3 | 2 |
| 15 | Moving forward with obesity research in breast cancer. <i>Breast</i> , 2017, 32, 225-226. | 2.2 | 1 |
| 16 | Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-504. | 1.6 | 1 |
| 17 | Association of obesity with breast cancer outcome in relation to cancer subtypes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11557-11557. | 1.6 | 1 |
| 18 | Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1520-1520. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute, 2022, , . | 6.3 | 0 |